{Reference Type}: Journal Article
{Title}: Non-criteria antiphospholipid antibodies and calprotectin as potential biomarkers in pediatric antiphospholipid syndrome.
{Author}: Sloan EE;Kmetova K;NaveenKumar SK;Kluge L;Chong E;Hoy CK;Yalavarthi S;Sarosh C;Baisch J;Walters L;Nassi L;Fuller J;Turnier JL;Pascual V;Wright TB;Madison JA;Knight JS;Zia A;Zuo Y;
{Journal}: Clin Immunol
{Volume}: 261
{Issue}: 0
{Year}: 2024 04 13
{Factor}: 10.19
{DOI}: 10.1016/j.clim.2024.109926
{Abstract}: Our study aimed to evaluate the presence, clinical associations, and potential mechanistic roles of non-criteria antiphospholipid antibodies (aPL) and circulating calprotectin, a highly stable marker of neutrophil extracellular trap release (NETosis), in pediatric APS patients. We found that 79% of pediatric APS patients had at least one non-criteria aPL at moderate-to-high titer. Univariate logistic regression demonstrated that positive anti-beta-2 glycoprotein I domain 1 (anti-D1) IgG (p = 0.008), anti-phosphatidylserine/prothrombin (aPS/PT) IgG (p < 0.001), and aPS/PT IgM (p < 0.001) were significantly associated with venous thrombosis. Positive anti-D1 IgG (p < 0.001), aPS/PT IgG (p < 0.001), and aPS/PT IgM (p = 0.001) were also associated with non-thrombotic manifestations of APS, such as thrombocytopenia. Increased levels of calprotectin were detected in children with APS. Calprotectin correlated positively with absolute neutrophil count (r = 0.63, p = 0.008) and negatively with platelet count (r = -0.59, p = 0.015). Mechanistically, plasma from pediatric APS patients with high calprotectin levels impaired platelet viability in a dose-dependent manner.